David Simonds, MD
Critical Care Medicine · Greensboro, NCNPI 1831148295
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 39 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $561 and has fallen 74.2% since, to $145 in 2025.
Across 39 payments — averaging $24.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$145
- Johnson & Johnson$118
- AstraZeneca$75
- Actelion Pharmaceuticals US, Inc.$63
- Mylan Specialty L.p.$53
- Genentech USA, Inc.$49
- plus $463 from 17 others
What the payments were for
- Food & beverage$965100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 1 | $145 |
| Johnson & Johnson | 1 | $118 |
| AstraZeneca(2 entities) | 4 | $75 |
| Actelion Pharmaceuticals US, Inc. | 3 | $63 |
| Mylan Specialty L.p. | 3 | $53 |
| Genentech USA, Inc. | 3 | $49 |
| Boston Scientific | 1 | $40 |
| Phadia US Inc. | 2 | $34 |
| Vifor Pharma, Inc. | 1 | $34 |
| Pfizer | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| Circassia Inc. | 2 | $31 |
| AbbVie | 2 | $31 |
| GSK | 2 | $30 |
| Resmed Corp | 1 | $30 |
| Sunovion Pharmaceuticals Inc. | 2 | $29 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| Novartis | 1 | $24 |
| Philips North America LLC | 1 | $21 |
| Portola Pharmaceuticals, LLC | 1 | $17 |
| Merck | 1 | $17 |
| Fresenius USA Marketing, Inc. | 1 | $16 |
| La Jolla Pharmaceutical Company | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$118
How this compares
$965 in reported general payments places this provider in the 70th percentile of 190 critical care medicine providers in North Carolina.
See all critical care medicine providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other critical care medicine in Greensboro
- Ravi AgarwalaGreensboro$1K
- Elias AshameGreensboro$818
- Alexis SmithHuntersville$726K
- Rabih BecharaCharlotte$453K
- Ashish KhannaWinston Salem$364K
- Alan HeffnerCharlotte$326K
- Daniel FeinsteinPinehurst$213K
- Daniel FoxRaleigh$133K
- Hassan YousafWinston Salem$97K
- Neil MacintyreDurham$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.